Collagen Matrix Inc. Acquires Polyganics

Collagen Matrix Inc., a leader in regenerative medicine and a Linden Capital Partners portfolio company, has acquired Polyganics, B.V., a medical technology company that develops and manufactures bioresorbable medical devices. The acquisition expands Collagen Matrix’s portfolio of bioresorbable solutions and technology platforms for bone and tissue repair, unlocking new markets and clinical opportunities for the company. 
 
“We’re laser focused on establishing Collagen Matrix as a global leader in regenerative medicine solutions,” said Shawn McCarthy, CEO of Collagen Matrix. “Polyganics is our third acquisition since Linden’s investment three years ago.”
 
Collagen Matrix has established an innovation pipeline to meet the clinical needs of physicians across several verticals including dental, orthopedic, spine, dural repair, nerve repair, sports medicine, and advanced wound care. With the addition of Polyganics’ versatile polymer platform, Collagen Matrix will enter ear, nose and throat (ENT) and general surgery while expanding its offerings for neurosurgery and peripheral nerve — and will have the opportunity to deliver products that bring benefits of collagen plus polymers.
 
“This transaction broadens our breadth of capabilities significantly with new processes, technologies and products,” added McCarthy. “We add value to our customers immediately by meeting a wider range of clinical needs.  This transaction also fuels our innovation pipeline so we can continue bringing a number of new products to market each year.” Continued Jeff Nelson, chairman of the Board of Collagen Matrix and Linden Operating Partner, “We have the opportunity to redefine what’s possible for regenerative medicine while making a meaningful difference in the lives of more patients around the world.”
 
Polyganics’ 75 employees will join the Collagen Matrix team, effective immediately, bringing Collagen Matrix’s total employee count to more than 275 people across five sites globally including Polyganics’ operations in The Netherlands.
 
“This transaction is testament to the value of Polyganics’ portfolio of innovative bioresorbable medical devices,” commented Rudy Mareel, CEO of Polyganics. “I am incredibly proud of the talented team we have brought together and the pioneering technology we have developed and championed. I have full confidence that Collagen Matrix is the right partner for us in the next phase of the Company’s journey.”
 
He continued, “this transaction will benefit both Polyganics’ employees and clients, by providing the necessary resources to drive further growth and important new research programs. It will also bring value to the local region of Groningen, where we have had the privilege to grow our business, and the Zernike Campus, where we opened our new $25M state-of-the-art facility last year.”
 
Linden Principal and Collagen Matrix Board Member, Joshua Reilly, added, “We couldn’t be more excited to partner with the Polyganics organization. This acquisition advances the strategy we began with the GUIDOR brand acquisition in 2020 to expand the range of technologies that we can offer to customers across a growing number of end markets.”
 
Financial details of the transaction were not disclosed.